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Abstract
Glaucoma is a silent condition very rarely presenting with headaches and only leading to decreased vision in the 
very advanced stages. Disc cupping and intraocular pressure measurement are important features in making the 
diagnosis. Acute angle closure is very rare and needs urgent referral. Most patients will be well controlled with 
medical therapy alone
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Introduction
Glaucoma is the second leading 
cause of blindness in the world, 
only being surpassed by cataract 
blindness, which, unlike glaucoma, 
is surgically curable.1 It is an optic 
neuropathy that is characterised 
by structural optic disc changes 
and visual field loss and is usually 
associated with an increased in-
traocular pressure, although not 
always (a common misconception). 
Other common misconceptions 
about glaucoma are summarised 
in Box 1. The most common form 
of glaucoma is primary open angle 
glaucoma, which is associated with a 
raised intraocular pressure. Patients 
with normal intraocular pressure but 
with field loss or glaucomatous disc 
changes are referred to as having 
normal tension glaucoma. Primary 
angle-closure glaucoma is much 
rarer and is found in patients who 
are predisposed due to specific 
anatomical features of the anterior 
part of the eye. It is generally more 
common in Asia and is found in South 
Africa in persons of mixed ancestry 
and in the Cape Malay population. 
There are other types of obstruction 
to aqueous outflow commonly cau-
sed by trauma or inflammation. We 
are beginning to understand the 
multifactorial causes of glaucoma 
(other than purely raised intraocular 
pressure) and the complex neuronal 
messaging responsible for premature 
ganglion cell death. At present, 
the only treatment available is 
lowering of the intraocular pressure, 
although the body of evidence for 
“neuroprotection” as an intervention 
is growing. 
1. Glaucoma is always caused  
 by high intraocular pressure
2. Headache is a frequent  
 presentation of glaucoma
3. Poor vision is a common  
 presentation of glaucoma
4. Visual fields detect early  
 glaucomatous damage
5. Untreated high intraocular  
 pressure leads to blindness  
 from glaucoma
Box 1: Common misconceptions 
about glaucoma
Prevalence
The prevalence of glaucoma in the 
American population is 1.5% to 2%, 
with 10% to 15% of first-degree 
relatives of patients diagnosed with 
primary open angle glaucoma likely 
to go on to develop the disease.2 
Two population-based surveys 
undertaken in Elim, Limpopo 
(1985) and in the Ingwavuma 
district in KwaZulu-Natal (1991) 
to determine the prevalence and 
causes of blindness saw glaucoma 
as the cause in 6% and 23% of 
cases respectively.3 In the planning 
of blindness prevention programmes 
in South Africa, a figure of 10% is 
used for blindness due to glaucoma. 
Glaucoma is the only common cause 
in the top three causes of blindness in 
both the first world (Europe and North 
America) and in the developing world 
(Latin America, Asia and Africa). Data 
from the United States estimates 
that 2.25 million Americans aged 40 
years and older have glaucoma, half 
of which are unaware that they have 
this disease.2 Elevated intraocular 
pressure affects an estimated 5 to 
10 million Americans, putting them at 
greater risk of developing glaucoma.2 
In the USA, more than 3 million visits to 
ophthalmologists are made to monitor 
glaucoma/intraocular pressure, and 
more than 1 million patients are on 
treatment.2
Screening and diagnosis
There is no easy screening tool 
with high specificity and sensitivity 
available for glaucoma as yet, 
although there are numerous trials 
underway evaluating new visual field 
testing technology, usually combined 
with optic disc appearance and/or 
intraocular pressure measurement. 
Visual field testing with the current 
standard technology can only detect 
glaucomatous damage after a 
significant amount of retinal ganglion 
cells (>50%) has already been lost. 
The appearance of the optic nerve 
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will usually alert the physician to 
the suspicion of glaucoma, as this 
structural loss will be seen before 
there is any functional loss. Disc 
appearance is the most accurate 
method of assessing whether or not 
a patient has glaucoma. The vision 
as measured by conventional acuity 
testing is usually unaffected until late 
in the disease process, unless the 
visual field loss encroaches onto the 
fixation point early on. 
Patients should be referred to an 
ophthalmologist if any of the following 
features are found on examination:
1. Increased cup-disc ratio 
(see Figure 1)
2. Haemorrhages at disc (see 
Figure 2)
3. Raised intraocular pressure
4. Visual field deficits
The glaucomatous optic disc is 
diagnosed when there is:
1. Increased cup to disc ratio 
2. Optic disc haemorrhages
3. Peripapillary atrophy
Most glaucoma is detected by 
optometrists, who usually screen 
intraocular pressure with an air-puff 
tonometer as a routine part of their 
examination, or it is detected in 
individuals who have been identified 
as at risk due to a family history and 
are being monitored. These patients 
would usually then be referred to an 
ophthalmologist, who would follow 
them up and initiate treatment if and 
when required. The air-puff tonometer 
tends to overestimate the intraocular 
pressure, particularly in patients with 
a strong blink reflex. It is important to 
remember that the majority of patients 
with a raised intraocular pressure 
(above 20 but less than 30) will not 
go on to develop glaucoma and are 
referred to as ocular hypertensives. 
They are at increased risk of glaucoma, 
however, and usually require lifelong 
follow up. Contrary to popular belief, 
most forms of glaucoma are not 
associated with headache and the 
vast majority of patients are totally 
free of any symptoms of a higher than 
normal intraocular pressure, except in 
the case of a sudden rise in pressure 
as occurs in an attack of angle-closure 
glaucoma (see box 2).
around lights due to corneal 
oedema.
4.  Anterior chamber may appear 
shallow.
5.  Urgent decrease in intraocular 
pressure – administer Aceta-
zolamide 500 mg IVI stat (if 
available) or alternatively 
Acetazolamide 500 mg po-
stat.
6.  Patients usually require anti-
emetics.
7.  Urgent referral to ophthal-
mologist required.
8.  Unless there is a delay in 
transfer, there is usually no 
need to administer Pilocarpine 
drops, as they usually are not 
effective when the intraocular 
pressure is above 50 mm 
Hg due to iris ischaemia. 
Should there be a delay, start 
Pilocarpine 2% qid in both 
eyes, as the fellow eye is 
usually also at risk.
Normal disc with healthy rim.
Cup : disc ratio of approximately 0.2
Early cupping-note thinner rim and 
increased cup : disc ratio of approxi-
mately 0.7
Advanced cupping (0.9)-note pallor 
of disc and barely discernible rim 
shown by veins dipping backwards 
over rim. 
Figure 1: Progressive optic disc cupping
Box 2: Diagnosis and treatment of 
acute angle-closure glaucoma
1.  Presents with sudden onset 
of severe pain in affected eye, 
with headache, nausea and 
vomiting. 
2.  Affected eye red with mid-size 
pupil unresponsive to light 
and hazy cornea.
3.  Patient may describe halos 
Treatment
The aim with glaucoma therapy is 
to detect the disease early on and 
thus prevent irreversible optic nerve 
damage with resultant visual field 
defects. The only modifiable risk 
factor (in terms of evidence-based 
medicine at present) that can be 
treated is intraocular pressure. This 
is achieved in the majority of ca-
ses through medical therapy, with 
surgery usually being reserved for 
when medical treatment fails or for 
intolerance to medical therapy. The 
only form of glaucoma that neces-
sitates emergency treatment is that 
in which there is a sudden increase in 
intraocular pressure, in which case the 
patient will present with severe pain, 
usually accompanied by headache, 
nausea and vomiting. The eye will 
be red, with a mid-dilated pupil not 
responsive to light.
Medical ion
P r o s t a g l a n d i n s / p r o s t a m i d e s 
(latanoprost, bimatoprost, travaprost)
This group of drugs is the treatment 
of choice in most cases and has the 
best efficacy in terms of lowering the 
intraocular pressure by increasing 
aqueous outflow from the eye and 
in terms of having the fewest side 
effects. These drugs also have 
the easiest dosing, with a once-
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a-day application. There are very 
few contraindications to these 
medications and the main side 
effects that have been noticed are 
an initial conjunctival injection, which 
usually settles with time, darkening 
of the iris colour and longer, thicker 
eyelashes. 
Topical beta blockers
Prior to prostaglandins, topical 
beta blocker therapy was the gold 
standard. This group of medi-
cations works by decreasing 
aqueous production and is dosed 
twice daily. The contraindications 
are as for systemic beta blockers 
(although betaxolol is marketed as 
a beta-1 selective agent with less 
bronchoconstrictive effect).
Carbonic anhydrase inhibitors
This group of drugs may be given 
topically or systemically to reduce 
aqueous humour production.
Topical: Dorzolamide and Brinzola-
mide
Systemic: Acetazolamide. Due to the 
side-effect profile, this is usually only 
used temporarily or in an emergency 
where a large drop in intraocular 
pressure is required in a short space 
of time.
Fixed combination drops (Dorzo-
lamide+Timolol and Latano-
prost+Timolol)
Both the prostaglandins and 
carbonic anhydrase inhibitors are 
available in a fixed combination with 
beta blockers. These may help with 
compliance issues, and are also 
slightly more effective.
Alpha agonists (brimonidine, aprac-
lonidine)
These agents work by decreasing 
aqueous humour production and 
increasing aqueous outflow. It is 
thought that these agents may have 
neuroprotective properties.
Miotics (pilocarpine)
This drug is seldom used today, 
although it may still be useful in 
angle-closure glaucoma patients. It 
has a poor side-effect profile and a 
laborious dosing regimen, at three to 
four times daily.
Hyperosmotic agents (mannitol, 
isosorbide, glycerol)




Lasers may be used to create a small 
hole, called a peripheral iridotomy 
(PI), in the peripheral iris to allow 
aqueous trapped behind the iris to 
circulate into the anterior chamber 
and drain out via the normal outflow 
pathway. This is most commonly 
performed in angle-closure glaucoma 
patients. Laser may also be applied 
to the trabecular meshwork in what is 
called laser trabeculoplasty (Argon 
laser trabeculoplasty or selective 
laser trabeculoplasty) to increase 
outflow.
Filtration surgery
Trabeculectomy is the gold standard 
for glaucoma filtering surgery (see 
Figure 3). It entails the creation of 
a small ostium underneath a flap 
of sclera that allows aqueous to 
slowly drain out of the eye and 
into the subconjunctival space. 
The problem with this surgery is 
that most eyes eventually become 
so scarred that the ostium closes, 
unless an antimetabolite is used 
intraoperatively. The latter, however, 
produces its own complications, 
such as late wound leaks and the 
threat of infection. 
Seton implants are tubes implanted 
into the anterior chamber that 
communicate with the subconjunctival 
space via a plate, which creates a 
reservoir into which the aqueous 
drains. Some of these implants may 
have a valve mechanism to prevent 
over-drainage and the complications 
of a hypotonic eye. The tubes seem 
to have a similar “survival” rate to a 
trabeculectomy, although there is 
a lot of work being done on these 
valves at present to produce a more 
predictable and long-lasting drainage 
device.
Conclusion
Glaucoma is the second leading 
cause of blindness and can usually 
be prevented by simple screening 
methods of intraocular pressure 
measurement and visualization of 
the optic disc at a primary care 
level effecting appropriate referral to 
ophthalmology services for further 
management. 
See CPD Questionnaire, page 50
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Figure 3: Trabeculectomy surgery site – note conjunctival ‘bleb’ filtering aqueous 
under the conjunctiva and the peripheral iridectomy.
